BIO Launches ‘Fight of Our Lives’: The Real Stories, Power, and Promise of American Biotech at a Defining Moment
The Biotechnology Innovation Organization (BIO) has launched the "Fight of Our Lives" campaign, using real patient narratives to underscore the impact of American biotech. The initiative features three inaugural stories—a rare‑genetic condition treated with targeted gene therapy, the first CAR‑T trial for multiple sclerosis, and an antibiotic‑resistant infection prompting AI‑driven drug research. BIO frames these cases as evidence of the sector’s historic breakthroughs and a rallying cry to sustain innovation. The campaign also warns that policy uncertainty and rising global competition could jeopardize future advances.
BIO Coffee Chat Explores Venture Philanthropy
The Biotechnology Innovation Organization (BIO) hosted a Patient Advocacy Coffee Chat highlighting the growing influence of venture philanthropy in biotech. Patient groups are now acting as investors, using capital and disease expertise to de‑risk early‑stage programs and guide trial design....
BIO Coffee Chat: Price Controls Like MFN Harm Access, Increase Costs
BIO’s March Coffee Chat highlighted how recent U.S. drug‑price policies, including the Inflation Reduction Act’s out‑of‑pocket cap and proposed Most Favored Nation (MFN) pricing models, are unintentionally raising patient costs and tightening access. Evidence shows beneficiaries often pay more than...
BIO’s Comments for USTR Report Highlight Global Threats to Intellectual Property
The Biotechnology Innovation Organization (BIO) submitted comments to the USTR’s 2026 Special 301 Report urging stronger global enforcement of intellectual‑property (IP) rights for biotech. BIO argues that weak IP protections in markets such as Colombia, Russia and Brazil create barriers...
Biotech Innovation Makes Inroads Against Bleeding Disorders
Biotech breakthroughs have transformed bleeding disorders from fatal diagnoses into manageable chronic conditions, with extended‑half‑life clotting factors, subcutaneous non‑factor drugs, and emerging gene therapies extending dosing intervals to weeks or months. The National Bleeding Disorders Foundation’s Pathway to Cures fund...
BIO CEO Hails Congressional Report on Threat of China Dominating Biotech
At a March 25 reception marking the first anniversary of the National Security Commission on Emerging Biotechnology report, BIO President John F. Crowley warned that China’s rapid biotech expansion threatens U.S. health security. The commission’s findings cite a 400‑fold rise...
Poll: U.S. Voters Want PBM and Insurance Reform—And Strong Biotech
A new Biotechnology Innovation Organization poll of 1,000 U.S. voters shows eight in ten would back leaders who lower drug costs by reforming pharmacy‑benefit managers, insurers, and the 340B program. Across party lines, 88% support passing PBM rebates directly to...
SBIR Reauthorization, a Top BIO Priority, Is Passed by Congress
Congress passed the reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs on March 17, securing five more years of federal seed funding for biotech startups. The bipartisan House vote was 345‑41 after a...
BIO on the American Road in Puerto Rico: ‘Medicine Cabinet’ Ready to Reshore
BIO President John F. Crowley toured Puerto Rico in March, highlighting the island’s role as “America’s Medicine Cabinet.” The territory already ships nearly one‑fifth of U.S. drug exports and accounts for about 30% of its GDP. Recent announcements from Amgen...
BIG Summit Panel Breaks Down Risks and Opportunities Coming Out of DC
At the inaugural BIO BIG Summit, a Washington Policy Brief panel dissected the shifting U.S. healthcare landscape for biotech. The discussion highlighted progress on reauthorizing the Prescription Drug User Fee Act (PDUFA) and emerging pharmacy benefit manager (PBM) reforms, while...
The Hidden Layer of PBMs: What a Recent Investigation Reveals
A recent Hunterbrook Media investigation uncovered a hidden layer of pharmacy benefit manager (PBM)‑affiliated group purchasing organizations (GPOs) that channel billions of dollars while maintaining minimal staff and opaque operations. The report shows the three largest PBMs, which already control...
BIO Patient Advocacy Coffee Chat: Act Now to Be Heard on CMS Drug Pricing
The Centers for Medicare & Medicaid Services entered the third year of its Medicare drug price negotiation program, selecting 15 drugs—including, for the first time, therapies covered under Medicare Part B. Patient advocacy groups have until March 1 to submit written comments...
Music Beats Cancer Aims to Bring Everyone to the Stage
Music Beats Cancer, a nonprofit founded by former cancer researcher Mona Jhaveri, uses live music and a peer‑to‑peer platform to funnel public donations directly to early‑stage biotech firms tackling cancer. By turning song likes into dollars, the organization bridges the...
The BIG Summit Meets at the Intersection of Patient Advocacy and Venture Investment
At the BIO Investor Growth (BIG) Summit, IBD Ventures’ associate director Nicole Schwerbrock discussed how venture philanthropy and patient advocacy are reshaping investment in inflammatory bowel disease (IBD) research. She explained that patient‑driven funding models complement traditional venture capital by...
NIH Director Says No Studies Link Vaccines and Autism, Outlines Modernization
NIH Director Jay Bhattacharya told the Senate HELP Committee that no scientific study links any vaccine to autism, reaffirming the consensus after senators raised vaccine‑safety concerns. He used the hearing to unveil a modernization agenda that includes centralizing peer review,...
